ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 154 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 7.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,845,111 | -36.2% | 5,313,915 | +0.0% | 0.20% | -37.1% |
Q2 2023 | $26,408,095 | +143.8% | 5,313,500 | +142.4% | 0.31% | +112.9% |
Q1 2023 | $10,830,604 | -41.1% | 2,192,430 | -25.0% | 0.15% | -40.2% |
Q4 2022 | $18,375,996 | -62.4% | 2,921,462 | -35.5% | 0.25% | -64.0% |
Q3 2022 | $48,885,000 | -26.8% | 4,526,422 | -22.8% | 0.68% | -33.6% |
Q2 2022 | $66,800,000 | +1596.7% | 5,859,679 | +1255.9% | 1.03% | +1507.8% |
Q1 2022 | $3,937,000 | -47.2% | 432,150 | -13.6% | 0.06% | -40.2% |
Q4 2021 | $7,461,000 | -64.3% | 500,095 | -38.5% | 0.11% | -68.6% |
Q3 2021 | $20,887,000 | +17.0% | 812,730 | +18.7% | 0.34% | +2.4% |
Q2 2021 | $17,858,000 | -24.8% | 684,755 | +1.8% | 0.33% | -36.8% |
Q1 2021 | $23,744,000 | +65.8% | 672,644 | +18.5% | 0.53% | +38.7% |
Q4 2020 | $14,325,000 | -5.1% | 567,539 | +41.8% | 0.38% | -23.2% |
Q3 2020 | $15,093,000 | +174.0% | 400,233 | +211.2% | 0.50% | +127.1% |
Q2 2020 | $5,508,000 | – | 128,628 | – | 0.22% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VV Manager LLC | 1,798,163 | $76,997,000 | 67.53% |
Wildcat Capital Management, LLC | 1,515,524 | $64,895,000 | 22.42% |
TPG Group Holdings (SBS) Advisors, Inc. | 19,716,306 | $844,252,000 | 14.91% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 1,279,281 | $54,779,000 | 7.69% |
Coastal Bridge Advisors, LLC | 463,117 | $19,831,000 | 6.33% |
DSAM Partners (London) Ltd | 235,098 | $10,067,000 | 2.63% |
Casdin Capital, LLC | 625,000 | $26,763,000 | 1.58% |
Alpine Global Management, LLC | 150,000 | $6,423,000 | 1.13% |
Perceptive Advisors | 1,543,790 | $66,105,000 | 1.07% |
Avoro Capital Advisors LLC | 1,128,594 | $48,326,000 | 0.96% |